» Articles » PMID: 29113178

Immunohistochemical Profile and Prognostic Significance in Primary Central Nervous System Lymphoma: Analysis of 89 Cases

Overview
Journal Oncol Lett
Specialty Oncology
Date 2017 Nov 9
PMID 29113178
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of primary central nervous system lymphomas (PCNSLs) are diffuse large B cell lymphoma, characterized by poor prognosis. In the present study, the expression of cluster of differentiation (CD)10, B cell lymphoma (BCL)-6, multiple myeloma-1 (MUM-1), BCL-2, CD138 and Ki-67 was analyzed by immunohistochemistry in 89 Chinese PCNSL cases, and the potential prognostic significance was evaluated. CD10, BCL-6, MUM-1, BCL-2 and CD138 were positive in 16.9 (15/89), 51.7 (46/89), 92.1 (82/89), 73.3 (63/86) and 0% (0/65) of all cases, respectively. According to the Hans algorithm, 71 patients (79.8%) were classified into the non-germinal center B cell-like (non-GCB) group, indicating a post-germinal center origin of PCNSL. The median follow-up time of 73 patients was 13 months [95% confidence interval (CI), 10.93-15.08]. The median overall survival (OS) time was 45.3 months (95% CI, 25.01-65.59) and the median progression-free survival (PFS) time was 30.0 months (95% CI, 13.43-46.57). Age (>60 years) was associated with a shorter OS time (P=0.009). Ki-67 (cutoff point 90%) was associated with shorter OS (P=0.037) and shorter PFS (P=0.039) times. No other immunohistochemical markers were associated with prognosis. On multivariate analysis, age (>60 years) was associated with shorter OS time (P=0.038), but immunophenotype and expression status of Ki-67, CD10, BCL-6 and BCL-2 did not predict prognosis. In conclusion, high Ki-67 expression may predict poor prognosis in PCNSL. The present study was limited by its sample size and short follow-up time. This requires more evidence to further clinical study.

Citing Articles

New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma.

Yang C, Ren X, Cui Y, Jiang H, Li M, Yu K Front Immunol. 2025; 16:1438001.

PMID: 40040699 PMC: 11876112. DOI: 10.3389/fimmu.2025.1438001.


Radiomics model building from multiparametric MRI to predict Ki-67 expression in patients with primary central nervous system lymphomas: a multicenter study.

Shen Y, Wu S, Wu Y, Cui C, Li H, Yang S BMC Med Imaging. 2025; 25(1):54.

PMID: 39962371 PMC: 11834475. DOI: 10.1186/s12880-025-01585-5.


MRI radiomics-based interpretable model and nomogram for preoperative prediction of Ki-67 expression status in primary central nervous system lymphoma.

Zhao E, Yang Y, Bai M, Zhang H, Yang Y, Song X Front Med (Lausanne). 2024; 11:1345162.

PMID: 38994341 PMC: 11236568. DOI: 10.3389/fmed.2024.1345162.


Updates of primary central nervous system lymphoma.

Wu J, Zhou D, Zhu X, Zhang Y, Xiao Y Ther Adv Hematol. 2024; 15:20406207241259010.

PMID: 38883164 PMC: 11177745. DOI: 10.1177/20406207241259010.


Extranodal lymphoma: pathogenesis, diagnosis and treatment.

Yang H, Xun Y, Ke C, Tateishi K, You H Mol Biomed. 2023; 4(1):29.

PMID: 37718386 PMC: 10505605. DOI: 10.1186/s43556-023-00141-3.


References
1.
Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

2.
Omuro A, Correa D, DeAngelis L, Moskowitz C, Matasar M, Kaley T . R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015; 125(9):1403-10. PMC: 4342354. DOI: 10.1182/blood-2014-10-604561. View

3.
Levy O, DeAngelis L, Filippa D, Panageas K, Abrey L . Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer. 2007; 112(1):151-6. DOI: 10.1002/cncr.23149. View

4.
Rubenstein J, Hsi E, Johnson J, Jung S, Nakashima M, Grant B . Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013; 31(25):3061-8. PMC: 3753699. DOI: 10.1200/JCO.2012.46.9957. View

5.
Miller T, Grogan T, Dahlberg S, Spier C, Braziel R, Banks P . Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994; 83(6):1460-6. View